Immunomonitoring and Predictive Biomarkers After CAR-T Cell Therapy in B-Cell Lymphoma and Multiple Myeloma

Official record

Identifier

NCT07852377

Recruiting locations

country

France

Interventions studied

Biological sample collection and immunomonitoring

Lead sponsor

Centre Henri Becquerel

Target enrolment

45 participants

Study type

INTERVENTIONAL

Phase

Not applicable

Status

Not yet recruiting

First posted

Oct 1, 2026

Last updated on the registry

Oct 1, 2026

Age

18 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Age 18 years or older.
* Relapsed or refractory B-cell lymphoma or multiple myeloma.
* Indication for anti-CD19 or anti-BCMA CAR-T cell treatment.
* Signed informed consent.
* Affiliation to or beneficiary status under a health insurance scheme.

Exclusion Criteria:

* Previous exposure to anti-BCMA bispecific antibodies or need for anti-BCMA bispecific antibodies as bridging therapy before anti-BCMA CAR-T cell administration.
* Pregnant or breastfeeding.
* Absence of informed consent.
* Primary central nervous system lymphoma or primary vitreoretinal lymphoma.
* Body weight below 30 kg.
* Protected adult or person deprived of liberty under guardianship or curatorship.
* Inability to understand the study or comply with study constraints for language, psychological, geographical or other reasons.

Indexed under

Lymphoma